Lucid Diagnostics Inc (LUCD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) has a cash flow conversion efficiency ratio of -1.034x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.30 Million) by net assets ($10.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lucid Diagnostics Inc (LUCD) market capitalisation for the company's overall valuation and market capitalisation.
Lucid Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Lucid Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lucid Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lucid Diagnostics Inc ranked by their cash flow conversion efficiency. See LUCD cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Black Rock Coffee Bar, Inc. Class A Common Stock
NASDAQ:BRCB
|
0.063x |
|
K2 Gold Corporation
V:KTO
|
-0.009x |
|
Stratus Properties Inc
NASDAQ:STRS
|
-0.045x |
|
Lavras Gold Corp
V:LGC
|
-0.018x |
|
Ram Essential Services Property Fund
AU:REP
|
0.018x |
|
Manulife Holdings Bhd
KLSE:1058
|
-0.011x |
|
PAN Group JSC
VN:PAN
|
0.370x |
|
Waterco Ltd
AU:WAT
|
0.044x |
Annual Cash Flow Conversion Efficiency for Lucid Diagnostics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lucid Diagnostics Inc from 2018 to 2025. View Lucid Diagnostics Inc (LUCD) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.94 Million | $-46.48 Million | -4.251x | +48.09% |
| 2024-12-31 | $5.39 Million | $-44.14 Million | -8.188x | -157.66% |
| 2023-12-31 | $-2.31 Million | $-32.82 Million | 14.200x | +1202.49% |
| 2022-12-31 | $23.05 Million | $-29.68 Million | -1.288x | -299.05% |
| 2021-12-31 | $54.74 Million | $-17.67 Million | -0.323x | -177.52% |
| 2020-12-31 | $-13.52 Million | $-5.63 Million | 0.416x | -6.38% |
| 2019-12-31 | $-5.31 Million | $-2.36 Million | 0.445x | +177.13% |
| 2018-12-31 | $-1.06 Million | $-170.55K | 0.160x | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more